OR WAIT null SECS
November 17, 2022
CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.
November 16, 2022
The deal will see Sanofi use Insilico’s AI drug discovery platform to advance up to six new drug development candidates.
Indivior’s acquisition of Opiant grants them access to the company’s portfolio of investigational opioid overdose reversal agent, OPNT003.
November 08, 2022
The collaboration will see Shimadzu and UMG develop new clinical laboratory methods using LC-MS for TDM analysis.
November 02, 2022
Gerresheimer and Nelson Labs will work together to conduct extractables and leachables testing on upcoming primary packaging solutions.
Under this deal, Merck, known as MSD outside of the United States and Canada, will select Veeva products for industry-specific software and data.
Johnson & Johnson’s acquisition of Abiomed, a provider of heart pump technologies, is designed to bolster their position in the medical technology sector.
Lonza and Singzyme will use Singzyme’s enzymatic conjugation platform to develop novel bioconjugates.
November 01, 2022
Purolite and Repligen have extended their existing ligand partnership through 2032.
October 28, 2022
The newly formed partnership between CSafe and BioLife will expand cold chain supply chain solutions for the cell and gene therapy market.